CD5L is a Potential Biomarker for Clinical Prognosis and Immunotherapy of Hepatocellular Carcinoma

Abstract

The CD5L molecule (CD5L), also known as macrophage apoptosis inhibitor (AIM), has multiple functions in lipid metabolism and inflammatory processes. However, there is a lack of evaluation of CD5L in human tumors, especially its predictive role in HCC progression. The expression of CD5LmRNA in patients with hepatocellular Carcinoma was searched by The Tumor Genome Atlas (TCGA) database. CD5L had significant protein interactions with FASN, CD163, STAB2, and LILRB5, which were retrieved by the timer database. The relationship between CD5L survival and prognosis in HCC and hepatitis was analyzed by the KaplanMeier database. CD5L enrichment was analyzed by KEGG, Biological processes, Molecular functions, and Cellular components. CD5L expression was low in tumor tissues and high in neighboring tissues, showing a tumor inhibitory effect. Low expression of CD5L in patients with hepatitis is associated with poor prognosis. TP53 mutations with low CD5L expression accounted for a high proportion of HCC. The high expression of CD5L promotes the infiltration of CD4+ T cells, CD8+ T cells, macrophages, Tfh, and other cells, causing an immune response. We comprehensively evaluated the role of CD5L biomarkers in HCC, and CD5L may be a new target for tumor immunotherapy.